Observed Signal · Aug 5, 2026 · Product Launch · Source: Modern Retail · Impact: 2/5 · Sentiment: Positive
Hims & Hers' Prescription Gummy Drives High Adherence
Hims & Hers launched a prescription Biotin + Minoxidil gummy for hair growth in June 2025. One year after launch the company surveyed 300 customers and reported an 88% daily adherence rate; 79% cited the green apple flavor as a reason for continued use and about two-thirds said the frosted glass jar packaging improved their experience. The article describes manufacturing and formulation challenges in creating a prescription-grade gummy and notes Hims & Hers' broader strategy of using design to de-stigmatize prescription products. The company reported $608.1 million in Q1 revenue in its May earnings report and gave full-year guidance of $2.8 billion to $3 billion.
Shows a D2C pharmaceutical product using CPG design to drive adherence and consumer acceptance; relevant to product design, packaging, and D2C pharma/CPG strategy but not industry-shifting.
Track Hims & Hers Signals & Market Shifts in Real-Time
Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your Polaris7 workspace to monitor these entities.
Key Takeaways & Evidence Grounding
- Hims & Hers launched the Biotin + Minoxidil Gummy (prescription) in June 2025.
- Hims & Hers surveyed 300 customers and reported an 88% daily adherence rate for the gummy.
- 79% of surveyed customers said the green apple flavor was a key reason they kept taking the gummy; nearly two-thirds said the frosted glass jar packaging made the experience more positive.
- Hims & Hers reported $608.1 million in revenue for the first quarter in its May earnings report and gave full-year guidance of $2.8 billion to $3 billion.
- Hims & Hers needed to acquire, tweak, and customize prescription-grade gummy manufacturing equipment to accurately dose each gummy.
Connected Companies & Entities
“When Hims & Hers launched the Biotin + Minoxidil Gummy for hair growth back in June 2025, it was the company’s first-ever attempt at a presc...”
“Gummies are also showing up in new places: Ulta’s new wellness boutique that piloted earlier this year, for instance, includes gummy wellnes...”
Ontology Mapping & Concepts
Related Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
Hims & Hers expands GLP-1 benefits with Tonal, Grüns, Viome, Medjet
Hims & Hers announced an expansion of its Hims & Hers Benefits program, adding four new brand partners: Tonal, Grüns, Viome, and Medjet. The program, launched in March, offers exclusive savings on health-related products and services to GLP-1 subscribers. It has grown from two to 14 brand partners. The company states it passes 100% of negotiated benefits to subscribers, not profiting from partnerships. Benefits include $1,000 off Tonal 2, $30 off Grüns first order, etc. The expansion aims to holistically support GLP-1 weight loss journeys, focusing on muscle maintenance and sustainable habits. Hims & Hers reported 13% YoY subscriber growth in Q3 2026, reaching 2.79 million. The program is part of a trend of platforms adding third-party perks for retention. Executive quotes highlight the value of integrated health support and customer acquisition for brand partners.
Hims & Hers Securities Fraud Class Action Filed
A securities fraud class action lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) in the U.S. District Court for the Northern District of California. The suit alleges the telehealth company disclosed sensitive health information to third-party advertising platforms, including Snap and Meta (Facebook), without proper consent, and misled consumers about billing practices. The FTC filed a related lawsuit on July 29, 2026, causing the stock to drop 14.73% to $25.00. Investors who purchased HIMS securities between August 4, 2025, and July 29, 2026, have until November 2, 2026, to apply as lead plaintiff. The case, Velanki v. Hims & Hers Health, Inc. et al., is being publicized by law firms including Kahn Swick & Foti, Kessler Topaz Meltzer & Check, and the Law Offices of Howard G. Smith.
Hims & Hers Securities Class Action Deadline Nov 2, 2026
Robbins Geller Rudman & Dowd LLP has announced a securities class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS), alleging violations of the Securities Exchange Act. The lawsuit, captioned Velanki v. Hims & Hers Health, Inc., is pending in the Northern District of California. It claims that the company made false statements and failed to disclose that it shared consumers' sensitive health information with third-party advertising platforms like Meta and Snap, and that it misled consumers about billing practices. Following an FTC lawsuit filed on July 29, 2026, the company's stock dropped nearly 15%. Investors who purchased securities between August 4, 2025 and July 29, 2026 have until November 2, 2026, to seek lead plaintiff appointment under the Private Securities Litigation Reform Act.
Receive all future signals for Hims & Hers & competitors in your briefing
Never miss material M&A deals, leadership changes, account wins, or product rollouts. Polaris7 monitors 20,000+ primary sources 24/7, delivering verified telemetry directly into your executive briefing.